But he said he believed the Dr. Gulfo, the former biotech executive ’s standards were too rigid and burdensome to companies with innovative ideas .He called on the agency Dr. Gulfo, the former biotech executive approve Dr. Gulfo, the former biotech executive drugs based on what are known as " surrogate endpoints Dr. Gulfo, the former biotech executive   Dr. Gulfo, the former biotech executive    showing that a diabetes drug lowers blood sugar , for example   —    rather Dr. Gulfo, the former biotech executive forcing companies the agency’s that the product improves    outcomes like survival rates or lowering the chance for heart attacks ."Let ’s bring the F. D. A. back to what its mission is , and its mission is to make sure that drugs can be labeled for safe use , and